NEW YORK, April 10, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Cemtrex, Inc. securities (NASDAQ:CETX) from October 26, 2016 through February 22, 2017, both dates inclusive (the “Class Period”) of the important April 25, 2017 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for Cemtrex investors under the federal securities laws.
To join the Cemtrex class action, go to http://www.rosenlegal.com/cases-1059.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendant Aron Govil’s role at Southern Steel & Construction Inc., which has been paying a notorious stock promoter, Small Cap Specialists, to promote Cemtrex’s stock; and (2) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. On February 22, 2017, Seeking Alpha published an article asserting that over $1 million has been paid to notorious stock promoters to promote Cemtrex, and Cemtrex’s founder, Defendant Aron Govil, is secretly paying promoters behind imploded frauds like Forcefield Energy and Code Rebel via an undisclosed entity. On this news, shares of Cemtrex fell $1.72 per share or over 33.5% from its previous closing price to close at $3.40 per share on February 22, 2017, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 25, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1059.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Attorney Advertising. Prior results do not guarantee a similar outcome.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Washington Post Publisher Will Lewis Steps Down After Layoffs
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



